wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q33405150-294E4583-EBCC-42DF-89B9-8EBBD72C2F17
Q33405150-294E4583-EBCC-42DF-89B9-8EBBD72C2F17
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33405150-294E4583-EBCC-42DF-89B9-8EBBD72C2F17
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
P2860
Q33405150-294E4583-EBCC-42DF-89B9-8EBBD72C2F17
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33405150-294E4583-EBCC-42DF-89B9-8EBBD72C2F17
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f17a767e018793d1656b4659e04b37152b9cf4b9
P2860
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.